• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Leishmaniasis/Kala Azar
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Leishmaniasis/Kala Azar
    • View Item
    Jan 17, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Comparison of Generic and Proprietary Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Kenya.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    moore.pdf
    Size:
    238.4Kb
    Format:
    PDF
    Download
    Authors
    Moore, E
    O'Flaherty, D
    Heuvelmans, H
    Seaman, J
    Veeken, H
    de Wit, S
    Davidson, R N
    Affiliation
    Médecins Sans Frontières-Holland (MSF-H) Kala-azar Programme, South Sudan/Kenya.
    Issue Date
    2001
    
    Metadata
    Show full item record
    Journal
    Bulletin of the World Health Organization
    Abstract
    OBJECTIVE: To compare the use of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis (kala-azar). METHODS: A total of 102 patients with confirmed kala-azar were treated in a mission hospital in West Pokot region, Kenya, with sodium stibogluconate (20 mg/kg/day for 30 days)--either as Pentostam (PSM) or generic sodium stibogluconate (SSG); 51 patients were allocated alternately to each treatment group. FINDINGS: There were no significant differences in baseline demographic characteristics or disease severity, or in events during treatment. There were 3 deaths in the PSM group and 1 in the SSG group; 2 patients defaulted in each group. Only 1 out of 80 test-of-cure splenic aspirates was positive for Leishmania spp.; this patient was in the SSG group. Follow-up after > or = 6 months showed that 6 out of 58 patients had relapsed, 5 in the SSG group and 1 in the PSM group. No outcome variable was significantly different between the two groups. CONCLUSION: The availability of cheaper generic sodium stibogluconate, subject to rigid quality controls, now makes it possible for the health authorities in kala-azar endemic areas to provide treatment to many more patients in Africa.
    Publisher
    Published by WHO
    URI
    http://hdl.handle.net/10144/17263
    PubMed ID
    11417033
    Additional Links
    http://www.who.int/bulletin/en
    Language
    en
    ISSN
    0042-9686
    Collections
    Leishmaniasis/Kala Azar

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.